Avastin vs Biosimilar Bevacizumab — Cost, Safety and CNS Use in India

WHO and EMA guidance supports switching between a biosimilar and its reference product. Some oncologists prefer not to switch mid-course without a clear clinical reason — not because of a known safety difference, but as a precaution while evidence on multiple switches continues to accumulate. If your centre proposes a switch, ask for the reason and confirm that your response will be assessed in the same way. A single switch, appropriately monitored, is not considered risky under current guidance from either body.

Avastin is the original product developed and licensed by Roche. Biosimilar manufacturers entered the market after the originator's data-exclusivity period expired, with a less costly development and approval pathway. That saving is reflected in the price. The active molecule, the mechanism and the efficacy standard required for approval are the same — you are paying for the brand and the originator's earlier investment, not for a clinically superior product.

Your oncologist decides that bevacizumab is the right treatment for you. Which specific product you receive is usually determined by what your hospital procures — an institutional decision, not a choice made individually each cycle. If you have a preference or a question, raise it before your first infusion. Most centres can tell you which product they stock and whether the alternative is available.

Yes, where the biosimilar carries CDSCO approval for those indications. Bevacizumab is used in glioblastoma and in some patients with brain metastases causing significant oedema. It works by blocking the blood supply to tumour vessels — not by crossing the blood-brain barrier directly. NCCN and ESMO guidance on bevacizumab in brain tumours does not distinguish between originator and approved biosimilar. Ask your oncologist whether the specific product your centre uses is approved for your indication.

The important ones are high blood pressure, protein in your urine (your team will monitor this with routine tests), slow wound healing, and a small risk of blood clots or, rarely, gut perforation. Report any headache that feels different from your usual, chest pain, swelling or pain in a limb, or a wound that is not healing. The side-effect profile is the same for originator and biosimilar — the risk comes from the molecule, not the manufacturer.

Ask your nurse or pharmacist before each infusion. The product name and manufacturer will be on the medicine bag or vial, and will be recorded in your medication chart. There is no reason to hesitate about asking — knowing which product and batch you received is particularly useful if you ever have a reaction that needs to be investigated. Your team should be able to tell you immediately.